Skip to main content
main-content

15-06-2022 | ASCO 2022 | Conference coverage | Video

Reflections on the DESTINY-Breast04 trial

share
SHARE

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved (5:02).